Davita Inc. Stock
Davita Inc. Stock
We can see a decrease in the price for Davita Inc.. Compared to yesterday it has lost -€3.800 (-3.000%).
With 1 Sell predictions and 1 Buy predictions the community sentiment towards the Davita Inc. stock is not clear.
A slightly negative potential of -2.86% at a current price of 122.5 € for Davita Inc. is the result of a target price of 119 €.
For the coming years our community has positive and negative things to say abot the Davita Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Davita Inc. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Davita Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Davita Inc. | -3.000% | -3.733% | -7.756% | -5.515% | 27.022% | 60.382% | 35.539% |
| Chemed Corp. | 0.000% | -6.509% | -8.671% | -39.231% | -13.187% | - | - |
| Select Medical Holdings | 0.740% | 0.000% | -0.725% | -4.196% | 9.600% | -45.635% | -53.082% |
| Teladoc Health Inc | 1.470% | 3.554% | -0.128% | -25.928% | -20.559% | -79.832% | -97.081% |
Comments
DaVita (NYSE:DVA) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for DVA provided by MarketBeat
DaVita (NYSE:DVA) had its price target lowered by analysts at Bank of America Corporation from $145.00 to $140.00. They now have an "underperform" rating on the stock.
Show more
Ratings data for DVA provided by MarketBeat
DaVita Inc. (NYSE: DVA) had its price target raised by analysts at UBS Group AG from $169.00 to $175.00. They now have a "buy" rating on the stock.
Show more
Ratings data for DVA provided by MarketBeat